You are here: Industry Insights > Market News > Additional 61,120 vials of Liposomal Amphotericin B allocated to states/UTs and central institutions: Gowda

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Vibegron Intermediate CAS:1421271-01-3

Food Grade Fish Collagen

Vibegron Intermediate CAS:1295539-30-8

Vibegron Intermediate CAS:1426235-01-9

Vibegron Intermediate CAS:163625-46-5

Vibegron Intermediate

Additional 61,120 vials of Liposomal Amphotericin B allocated to states/UTs and central institutions: Gowda

expresspharmaJune 25, 2021

Tag: Liposomal Amphotericin B , Mucormycosis , DV Sadananda Gowda

Favorites

The Union Minister for Chemicals and Fertilizers DV Sadananda Gowda 23rd announced that an additional 61,120 vials of Liposomal Amphotericin-B, used in the treatment for mucormycosis, have been allocated to all states/ Union Territories (UTs) and central institutions.

“Additional 61,120 vials of #LiposomalAmphotericinB have been allocated to all states/UTs and central institutions today. So far, approximately 7.9 lakh vials have been allocated across the country, maintaining adequate availability to patients of mucormycosis,” he wrote on Twitter.

Previous:Zydus Cadila receives tentative approval from USFDA for Fingolimod Capsules .25mg

Next:Cipla gets USFDA nod for inhalation product

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Additional 61,120 vials of Liposomal Amphotericin B allocated to states/UTs and central institutions: Gowda | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Additional 61,120 vials of Liposomal Amphotericin B allocated to states/UTs and central institutions: Gowda

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Additional 61,120 vials of Liposomal Amphotericin B allocated to states/UTs and central institutions: Gowda

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>